Mundipharma launches Invokana and Vokanamet in Norway to treat type 2 diabetes

In line with the partnership with Janssen Pharmaceutica NV, Mundipharma now exclusively distributes and markets these treatments across 18 countries in the European Economic Area (EEA) and Switzerland. With the launch in Norway, Invokana and Vokanamet are now available across the whole of Scandinavia, following the launches in Sweden and Denmark.

Invokana, a once-daily oral tablet, is part of the sodium glucose co-transporter 2 (SGLT2) inhibitor class and has been approved in the European Union since 2013.2 Vokanamet combines two oral glucose-lowering medicinal products (canagliflozin and metformin) with different and complementary mechanisms of action.

“We are delighted to extend our European footprint for Invokana and Vokanamet to provide healthcare professionals in Norway with two new treatment options to manage type 2 diabetes,” said Dr Vinicius Gomes de Lima, European Medical Affairs Lead. “Type 2 diabetes is a growing epidemic in Europe and effective treatments are needed to help reduce the burden of the disease in patients. Invokana and Vokanamet have shown improvement in glycaemic control and reduction of cardiovascular morbidity and mortality as well as improvements in renal outcomes which is of real importance in this disease.”

Approximately 58 million people in Europe currently live with T2DM, which is set to rise to 67 million by 2045. 1 If left untreated, patients are at greater risk of developing serious complications, such as cardiovascular (CV) disease and kidney failure.

Last year, the European Medicines Agency (EMA) approved label updates for Invokana and Vokanamet to include data on the reduction in major adverse CV events in patients with T2DM who had either a history of CV disease or at least two CV risk factors.5 The label update was supported by the results from the CANVAS clinical trial, the largest completed CV outcomes trial to date for an SGLT2 inhibitor.6 The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) also issued a Consensus Report in October 2018 which recommends SGLT2 inhibitors with a proven CV benefit as the preferred oral treatment after metformin for T2DM patients with chronic kidney disease (CKD) or clinical heart failure and atherosclerotic CV disease.

New data for canagliflozin from the CREDENCE study will be presented at the upcoming World Congress of Nephrology during the late-breaking abstract session on Monday 15th April. The study evaluated the effect of canagliflozin on renal protection in patients with T2DM and CKD.

Source: Company Press Release